First Trust NYSE Arca Biotech ETF (FBT)
151.35
-0.37
(-0.24%)
USD |
NYSEARCA |
Mar 18, 16:00
151.77
+0.42
(+0.28%)
After-Hours: 20:00
Price Chart
Key Stats
Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
0.56% | -0.05% | 1.175B | 29206.70 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
0.00% | 30.00% | -261.23M | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE ® Arca ® Biotechnology Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Mid Cap/Growth |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | First Trust Advisors L.P. |
Prospectus Benchmark Index | |
NYSE Arca Biotechnology TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Daniel Lindquist | 17.71 yrs |
David McGarel | 17.71 yrs |
Jon Erickson | 17.71 yrs |
Roger Testin | 17.71 yrs |
Stan Ueland | 17.32 yrs |
Chris Peterson | 7.96 yrs |
Erik Russo | 3.17 yrs |
Performance Versus Category
As of March 18, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 18, 2024.
Basic Info
Investment Strategy | |
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE ® Arca ® Biotechnology Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Mid Cap/Growth |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | First Trust Advisors L.P. |
Prospectus Benchmark Index | |
NYSE Arca Biotechnology TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Daniel Lindquist | 17.71 yrs |
David McGarel | 17.71 yrs |
Jon Erickson | 17.71 yrs |
Roger Testin | 17.71 yrs |
Stan Ueland | 17.32 yrs |
Chris Peterson | 7.96 yrs |
Erik Russo | 3.17 yrs |